Author(s): Neeli Parvathi, Rajitha Rajendran, Subramanian Iyyam Pillai, Sorimuthu Pillai Subramanian


DOI: 10.52711/0974-360X.2024.00004   

Address: Neeli Parvathi1, Rajitha Rajendran1, Subramanian Iyyam Pillai2, Sorimuthu Pillai Subramanian1*
1Department of Biochemistry, University of Madras, Guindy Campus, Chennai - 600025, India.
2P.G. and Research Department of Chemistry, Pachaiyappa’s College, Chennai - 600030.
*Corresponding Author

Published In:   Volume - 17,      Issue - 1,     Year - 2024

Type 2 diabetes mellitus (T2DM) is a worldwide public health crisis. The existing treatments have limitations such as undesirable side effects such as hypoglycemia, unusual weight gain and the development of resistance after prolonged use, which necessitates the development of new therapies for paramount glycemic control, especially those of plant origin. Avicularin, a plant flavonoid and a quercetin glycoside, was originally purified from Psidium guajava. It has been reported to elicit a wide range of pharmacological and beneficial properties especially striking antidiabetic activity. In-silico models have been recognized as being of fundamental importance in the area of research and development of drugs due to their applications both in the evaluation of bioactive substances and in relation to their physicochemical and pharmacokinetic properties, giving rise to a new model of drug design with greater value and efficiency. The aim of the present study was to analyze the molecular interactions between Avicularin andprominent target proteins involved in the commencement and development of diabetes and its secondary complications using an in silico approach.

Cite this article:
Neeli Parvathi, Rajitha Rajendran, Subramanian Iyyam Pillai, Sorimuthu Pillai Subramanian. In Silico Studies on the Antidiabetic activity of Avicularin. Research Journal of Pharmacy and Technology. 2024; 17(1):19-4. doi: 10.52711/0974-360X.2024.00004

Neeli Parvathi, Rajitha Rajendran, Subramanian Iyyam Pillai, Sorimuthu Pillai Subramanian. In Silico Studies on the Antidiabetic activity of Avicularin. Research Journal of Pharmacy and Technology. 2024; 17(1):19-4. doi: 10.52711/0974-360X.2024.00004   Available on:

1.    Vieira R, Souto SB, Sánchez-López E, López Machado A, Severino P, Jose S, Santini A, Fortuna A, García ML, Silva AM, Souto EB. Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—Review of classical and new compounds: Part-I. Pharmaceuticals. 2019;12(4):152.
2.    Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, delCañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World Journal of Diabetes. 2016;7(17):354.
3.    Alam S, Sarker MM, Sultana TN, Chowdhury MN, Rashid MA, Chaity NI, Zhao C, Xiao J, Hafez EE, Khan SA, Mohamed IN. Antidiabetic phytochemicals from medicinal plants: prospective candidates for new drug discovery and development. Frontiers in Endocrinology. 2022;13:800714.
4.    Granica S, Czerwińska ME, Żyżyńska-Granica B, Kiss AK. Antioxidant and anti-inflammatory flavonolglucuronides from Polygonumaviculare L. Fitoterapia. 2013;91:180-8..
5.    Parvathi N, Subramanian IP, Subramanian SP. Biochemical evaluation of antioxidant properties of a zn-avicularin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats. Research Journal of Pharmacy and Technology. 2023; 16(1):145-52.
6.    Guo XF, Liu JP, Ma SQ, Zhang P, Sun WD. Avicularin reversed multidrug-resistance in human gastric cancer through enhancing Bax and BOK expressions. Biomedicine & Pharmacotherapy. 2018;103:67-74..
7.    Pandhare RB, Sangameswaran B, Mohite PB, Khanage SG. Antidiabetic activity of aqueous leaves extract of Sesbaniasesban (L) Merr. instreptozotocin induced diabetic rats. Avicenna Journal of Medical Biotechnology. 2011;3(1):37.
8.    Kontoyianni M. Docking and virtual screening in drug discovery. Proteomics for drug discovery: Methods and Protocols. 2017:255-66.
9.    Bharath EN, Manjula SN, Vijaychand A. In silico drug design tool for overcoming the innovation deficit in the drug discovery process. Int J Pharm Pharm Sci. 2011;3(2):8-12.
10.    Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design. 2011;7(2):146-57.
11.    Mishra A, Dey S. Molecular docking studies of a cyclic octapeptide-cyclosaplin from sandalwood. Biomolecules. 2019; 9(11): 740.
12.    Vieira TF, Sousa SF. Comparing AutoDock and Vina in ligand/decoy discrimination for virtual screening. Applied Sciences. 2019;9(21):4538.
13.    Doliba NM, Qin W, Najafi H, Liu C, Buettger CW, Sotiris J, Collins HW, Li C, Stanley CA, Wilson DF, Grimsby J. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. American Journal of Physiology-Endocrinology and Metabolism. 2012;302(1):E87-102.
14.    Choi JM, Seo MH, Kyeong HH, Kim E, Kim HS. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proceedings of the National Academy of Sciences. 2013;110(25):10171-6.
15.    Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes. 2009 Jan;58(1):18.
16.    Matschinsky FM, Wilson DF. The central role of glucokinase in glucose homeostasis: A perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans. Frontiers in Physiology. 2019;10:148.
17.    Sharma P, Singh S, Sharma N, Singla D, Guarve K, Grewal AS. Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators. Journal of Diabetes & Metabolic Disorders. 2022; 21(1):1129-37.
18.    Mindnich RD, Penning TM. Aldo-ketoreductase (AKR) superfamily: genomics and annotation. Human Genomics. 2009; 3(4): 1-9.
19.    Akileshwari C, Muthenna P, Nastasijević B, Joksić G, Petrash JM, Reddy GB. Inhibition of aldose reductase by Gentianalutea extracts. Journal of Diabetes Research. 2012.
20.    Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Frontiers in pharmacology. 2012;3:87.
21.    Van Heyningen R. Formation of polyols by the lens of the rat with ‘sugar’cataract. Nature. 1959;184(4681):194-5.
22.    Varma SD, Kinoshita JH. Inhibition of lens aldose reductase by flavonoids—their possible role in the prevention of diabetic cataracts. Biochemical Pharmacology. 1976;25(22):250513.
23.    Tammali R, K Srivastava S, V Ramana K. Targeting aldose reductase for the treatment of cancer. Current Cancer Drug Targets. 2011;11(5):560-71.
24.    Escribano O, Beneit N, Rubio-Longás C, López-Pastor AR, Gómez-Hernández A. The role of insulin receptor isoforms in diabetes and its metabolic and vascular complications. Journal of Diabetes Research. 2017.
25.    Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. The Journal of Clinical Investigation. 2000;106(2):165-9.
26.    Virkamäki A, Ueki K, Kahn CR. Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. The Journal of Clinical Investigation. 1999;103(7):931-43.
27.    Trott O, Olson AJ. AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010;31(2):455-61.
28.    Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-aided Molecular Design. 2010;24(5):417-22.
29.    Hafeez A, Askari H, Khan N, Akram M, Hanif S, Urooj N. Molecular modeling of plant flavonoids as angiotensin converting enzyme (ACE) inhibitors in hypertension: A docking study. World Journal of Pharmaceutical Sciences. 2014 May 1:499-506.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available